<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Buckley, Rita</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Lewin, Andrew J.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Significant HbA1c Reduction With Empagliflozin/Linagliptin Combination</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2015-05-18 15:35:54</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">14-14</style></pages><abstract><style  face="normal" font="default" size="100%">Over a 24-week period, a combination of empagliflozin/linagliptin for the treatment of type 2 diabetes produced significant reductions in HbA1c compared with linagliptin and with empagliflozin 10 mg, but not empagliflozin 25 mg. This randomized trial suggests that this approach could be a more efficient way to achieve glycemic control.</style></abstract><number><style face="normal" font="default" size="100%">4</style></number><volume><style face="normal" font="default" size="100%">15</style></volume></record></records></xml>